HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Human epidermal growth factor receptor 2 ( HER2) is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with HER2 alterations: somatic mutations and amplifications. HER2 was first assessed as a biomarker of resistance to anti- EGFR therapy; however, in more recent years, its role as a potential actionable target has emerged. In this article, we discuss the predictive and prognostic value of HER2 in metastatic colorectal cancer, its emerging role as an actionable therapeutic target, and its possible future developments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, HER2 is commonly amplified or overexpressed in 7% to 47.4% of CRC patients, activating downstream signaling in a similar manner [81–83].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [83]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Self-citation
Research works printed but not linked: 10
- Laurent-Puig P, 2016, Ann Oncol, 27, Vi151
- Edenfield WJ, 2014, J Clin Oncol, 32
- Strickler JH, 2021, J Clin Oncol, 39
- Cavanna L, 2018, Oncol Lett, 15, 5787
- Clark JW, 2003, Onkologie, 26, 13
- Messersmith WA, 2019, J Natl Compr Cancer Netw, 17, 599
- Yoshino T, 2021, J Clin Oncol, 39
- Raghav KPS, 2021, J Clin Oncol, 39
- Li W, 2022, J Clin Oncol, 40
- Siena S, 2016, J Clin Oncol, 34
Cited by
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 669
Liquid biopsy epigenomic profiling for cancer subtyping
Baca, S. C., Seo, J.-H., Davidsohn, M. P., Fortunato, B. J., Semaan, K., Sotudian, S., Lakshminarayanan, G., Dióssy, M., Qiu, X., Zarif, T. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02605-z · Cited by 145
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“In fact, Cells 2024 , 13 , 245 9 of 16 the tucanitinib/trastuzumab combination was the topic of the MOUNTAINEER trial [70].”
BackgroundRubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Guaqueta, D. C., Naraine, A. M., & Ergle, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021064 · Cited by 85
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
Valenza, C., Guidi, L., Battaiotto, E., Trapani, D., Bianchi, A. S., Siena, S., & Curigliano, G. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.001 · Cited by 78
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta, A., Michelini, F., Shao, H., Yeh, C., Drago, J. Z., Liu, D., Rosiek, E., Romin, Y., Ghafourian, N., Thyparambil, S. P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101792 · Cited by 64
Casak, S. J., Horiba, M. N., Yuan, M., Cheng, J., Lemery, S. J., Shen, Y. L., Fu, W., Moore, J. N., Li, Y., Bi, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1041 · Cited by 43
Ivanova, M. D., Venetis, K., Guerini‐Rocco, E., Bottiglieri, L., Mastropasqua, M. G., Garrone, O., Fusco, N., & Ghidini, M. (2022) · Life · doi:10.3390/life12091403 · Cited by 40
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 34
Chary, P. S., Bhawale, R., Vasave, R., Rajana, N., Singh, P. K., Madan, J., Singh, S. B., & Mehra, N. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104588 · Cited by 33
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 30
Colorectal cancer spectrum: From subtypes and epidemiology to oncotherapies
Agrawal, N., Lanjhiyana, S. K., Jaiswal, M., Siddiqui, M. A., & Gupta, S. (2025) · Gastroenterology & Endoscopy · doi:10.1016/j.gande.2025.01.002 · Cited by 30
Ramzy, G. M., Norkin, M., Koessler, T., Voirol, L., Tihy, M., Hany, D., McKee, T., Ris, F., Buchs, N. C., Docquier, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02650-z · Cited by 29
HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study
Chen, P.-C., Yeh, Y., Chu, C., Su, P., Chiu, P.-H., Lin, B.-W., Chen, S., Lin, P., Lee, C., Chen, H. H. W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.019 · Cited by 27
Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 25
Sex Differences in Colon Cancer: Genomic and Nongenomic Signalling of Oestrogen
Harvey, B. J., & Harvey, H. M. (2023) · Genes · doi:10.3390/genes14122225 · Cited by 25
Kobecki, J., Gajdzis, P., Mazur, G. J., & Chabowski, M. (2022) · Diagnostics · doi:10.3390/diagnostics12123076 · Cited by 22
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Cutsem, E. V., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67824-z · Cited by 21
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier
Jones, L., Cunningham, D., & Starling, N. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102789 · Cited by 20
From Discovery to Diagnosis: A Perspective for Circulating Tumor Cells in Personalized Oncology
Alix‐Panabières, C., & Pantel, K. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0164 · Cited by 20
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 19
The importance of protein domain mutations in cancer therapy
Chitluri, K. K., & Emerson, I. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27655 · Cited by 18
Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Kano, Y., Suenaga, M., & Uetake, H. (2023) · Current Oncology · doi:10.3390/curroncol30070480 · Cited by 18
Qiang, Z., Wan, J., Chen, X., & Wang, H. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-837 · Cited by 18
Chitkara, A., Bakhtiar, M., Şahin, İ. H., Hsu, D. J., Zhang, J. Y., Anamika, F., Mahnoor, M., Ahmed, R., Gholami, S., & Saeed, A. (2023) · Current Oncology · doi:10.3390/curroncol30090600 · Cited by 18
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
Wang, R., Fang, P., Chen, X., Ji, J., Yu, D., Mei, F., Wang, Z., Zhou, W., Peng, W., Wang, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102213 · Cited by 17
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Revolutionizing Cancer Care: Advances in Carbon-Based Materials for Diagnosis and Treatment
Khan, M. Z., Tahir, D., Asim, M., Israr, M., Haider, A., & Xu, D. (2024) · Cureus · doi:10.7759/cureus.52511 · Cited by 17
Khelwatty, S. A., Puvanenthiran, S., Seddon, A. M., Bagwan, I., Essapen, S., & Modjtahedi, H. (2025) · Cancers · doi:10.3390/cancers17172810 · Cited by 15
Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100032 · Cited by 14
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
Patel, A., & Gulhati, P. (2024) · Cancers · doi:10.3390/cancers16081551 · Cited by 14
Germani, M. M., Borelli, B., Hashimoto, T., Nakamura, Y., Oldani, S., Battaglin, F., Bergamo, F., Salvatore, L., Stahler, A., Antoniotti, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01003 · Cited by 14
Self-citationKo, H. C., Strickland, K. C., Jaggessarsingh, D., Dillard, A., Green, M. F., Newburn, E. N., Sellaro, T. L., Klein, J. L., Caveney, B. J., Eisenberg, M. T., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1565872 · Cited by 13
Pilati, C., Soulabaille, A., Gallois, C., Blons, H., Cayre, A., Sroussi, M., Corre, D. L., Mouillet‐Richard, S., Mulot, C., Malicot, K. L., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.10.046 · Cited by 13
Scalambra, L., Ruzzi, F., Pittino, O. M., Semprini, M. S., Cappello, C., Angelicola, S., Palladini, A., Nanni, P., Goksøyr, L., Fougeroux, C. E., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06126-w · Cited by 12
Zheng, E., Włodarczyk, M., Węgiel, A., Osielczak, A., Możdżan, M., Biskup, L., Grochowska, A., Wołyniak, M., Gajewski, D., Porc, M., et al. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1398289 · Cited by 12
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
Ji, P., Chen, T., Li, C. R., Zhang, J., Li, X., & Zhu, H. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104586 · Cited by 11
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer
Hwang, S., Seo, Y., Park, S., Kim, S.-A., Moon, I., Liu, Y., Kim, S., Pak, E. S., Jung, S., Kim, H., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02343-5 · Cited by 11
Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI
Cataldi, C., Karaoğlan, B. B., Liotta, E., & Dosso, S. D. (2026) · Cancers · doi:10.3390/cancers18050852 · Cited by 11
Extracellular Nucleic Acids in the Diagnosis and Progression of Colorectal Cancer
Styk, J., Buglyó, G., Pös, O., Csók, Á., Soltész, B., Lukasz, P., Repiská, V., Nagy, B., & Szemes, T. (2022) · Cancers · doi:10.3390/cancers14153712 · Cited by 11
An update on pharmacotherapies for colorectal cancer: 2023 and beyond
Zhu, M., & Benson, A. B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2304654 · Cited by 11
Hu, T., Zhan, J., Li, L., He, Y., Lin, Y., Wang, J., Yu, H., Xiong, J., Fang, Z., Deng, J., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae020 · Cited by 11
Kusumaningrum, A. E., Makaba, S., Ali, E., Singh, M., Fenjan, M. N., Rasulova, I., Misra, N., Al‐Musawi, S. G., & Alsalamy, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3906 · Cited by 10
A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer
Okoye, C., Tran, M., Soladoye, E., Akahara, D. E., Emeasoba, C. M., Ojinna, B. T., Kelechi, A. E., Obadare, O. O., Diala, C. S., Salaudeen, B. H., et al. (2023) · Cureus · doi:10.7759/cureus.43189 · Cited by 9
Astore, M., Fabbri, L., Monte, A., Deiana, C., Rizzo, A., Tavolari, S., Deserti, M., Brandi, G., Palloni, A., & Frega, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411961 · Cited by 9
Araújo, R. L. C., da Fonseca, L. G., Silva, R. O., Linhares, M. M., & Usón, P. L. S. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-616 · Cited by 8
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan
Neupane, N., Thapa, S., Bhattarai, A., Ahuja, K., Schlam, I. M., Mittal, A., Tolaney, S. M., & Tarantino, P. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01469-3 · Cited by 8
Molekularpathologie kolorektaler Karzinome
Woischke, C., Michl, M., & Neumann, J. H. L. (2023) · Die Pathologie · doi:10.1007/s00292-023-01201-9 · Cited by 8
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Additionally, HER2 is commonly amplified or overexpressed in 7% to 47.4% of CRC patients, activating downstream signaling in a similar manner [83 – 85].”
InfluentialMagalhães, D., dos Santos, J., Frutuoso, A., & Mesquita, A. (2023) · Cureus · doi:10.7759/cureus.34724 · Cited by 7
Grandits, M., Palhares, L. C. G. F., Osborn, G., Chauhan, J., Stoker, K., Sow, H. S., Adams, R., McCraw, A. J., Chenoweth, A. M., Vlasova, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010945 · Cited by 7
Taştemur, Ş., Kaleci, A. O., Öztürk, A., & Mendĭl, A. S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02978-w · Cited by 7
Park, S. J., Shin, K., Hong, T. H., Lee, S. H., Kim, I.-H., Kim, Y.-H., & Lee, M. A. (2024) · Cancers · doi:10.3390/cancers16152756 · Cited by 7
Oku, D.-B. N. T., Babatunde, D. D., Nuapia, Y. B., More, G. K., & Chokwe, R. C. (2025) · ACS Omega · doi:10.1021/acsomega.5c07683 · Cited by 6
Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging
Ducharme, M., Mansur, A., Sligh, L., Ulaner, G. A., Lapi, S. E., & Sorace, A. G. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.04.009 · Cited by 6
LIU, Y., Bischof, E. Y., CHEN, Z., ZHOU, J., Zhang, B., Zhang, D., GAO, Y., & Quan, M. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.047309 · Cited by 5
Lobo-Castañón, M. J., & Díaz‐Fernández, A. (2025) · Biosensors · doi:10.3390/bios15110726 · Cited by 5
Grandes avances en el diagnóstico y tratamiento del cáncer colorrectal (CRC)
Jiménez, P., Canro, F., Bonilla, C., Ávila, V., & García‐Foncillas, J. (2024) · Medicina · doi:10.56050/01205498.2377 · Cited by 5
Radić, J., Nikolić, I., Kolarov-Bjelobrk, I., Vasiljević, T., Djurić, A., Vidović, V., & Kožik, B. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080879 · Cited by 5
Rudiman, R., Wijaya, A., Sribudiani, Y., Soedjana, H., Wiraswati, H. L., Primastari, E., Nugraha, P., & Lukman, K. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000694 · Cited by 5
Rinne, S. S., Vargas, D. B., Vaughn, B. A., Katugampola, S., Miller, B. W., Veach, D. R., Punzalan, B. J., de Stanchina, E., Yaeger, R. D., Miranda, I. C., et al. (2025) · Theranostics · doi:10.7150/thno.116062 · Cited by 5
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
Camera, S., Rossari, F., Foti, S., Vitiello, F., Persano, M., Prinzi, F. L., COBELLI, F. D., Aldrighetti, L. A., Cascinu, S., Rimini, M., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01132-w · Cited by 5
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
Sur, D. G., Lungulescu, C., Dumitrescu, E. A., Afrăsânie, V. A., Spînu, Ș., Lungulescu, C. V., & Schmoll, H. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2207830 · Cited by 4
Oncogenic mutations of clinical significance in colorectal cancer
Lea, V., Lim, S. H.-S., & Lee, C. S. (2025) · Pathology · doi:10.1016/j.pathol.2025.05.001 · Cited by 4
Camera, S., Rimini, M., Foti, S., Prinzi, F. L., Vitiello, F., Amadeo, E., Persano, M., Cascinu, S., Gardini, A. C., & Rossari, F. (2025) · Oncology · doi:10.1159/000545308 · Cited by 4
Hussain, A., Iqbal, Q., Isaac, S. P., Shariff, F. S., Tariq, E. F., Awais, H., Mainkar, N., Reis, H. L., Arora, A., Deotare, A., et al. (2025) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2025.1559934 · Cited by 3
Parente, P., Grillo, F., Callegarin, M., Luchini, C., Milione, M., Mattiolo, P., Gafà, R., Pagni, F., Malapelle, U., Macciomei, M. C., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.001 · Cited by 3
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Trembath, H. E., Yeh, J. J., & Lopez, N. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_15 · Cited by 3
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 3
Aptasensors in colorectal Cancer: Emerging tools for precision diagnostics
Abuhassan, Q., Atoom, A. M., Roopashree, R., Kanwar, J. B., Sudhakar, T., Sharma, V., Chauhan, A. S., & Ruziyev, O. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120751 · Cited by 3
Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor
Wang, Z., Chen, L., Rao, W., Cao, B., Cai, M., Fan, X., Ji, Y., Li, Y., Song, Y., Sun, Y., et al. (2026) · Cancer Innovation · doi:10.1002/cai2.70060 · Cited by 3
Kao, Y.-C. (2024) · American Journal of Cancer Research · doi:10.62347/ykzb8359 · Cited by 3
A study of the anticancer effect of 1,8 cineole: Molecular docking analysis
Bıçak, B. (2024) · Bilge International Journal of Science and Technology Research · doi:10.30516/bilgesci.1415844 · Cited by 3
Identification of novel diagnostic biomarkers in stages I-IV colorectal cancer
Sadighi, S. A., Abbasian, V., Sabbaghi, S. S., Azimi, M., & Ranjbary, A. G. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00716-5 · Cited by 3
Wang, S. H., Cao, Z., Janczak, K. W., Feng, Y., Green, M. E., Tang, S., Fearon, E. R., & Baker, J. R. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01035-6 · Cited by 2
Iyer, K. A., Tenchov, R., Ivanov, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.5c00693 · Cited by 2
Al-Shamsi, H. O., Rasul, K. I., Shablak, A., Alnajjar, A., Shabaan, A. M., Alsindi, M., Nasr, M., AlJabban, A., & Rafii, S. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s535858 · Cited by 2
Sulaiman, R. A., Aske, J. C., Espaillat, L. R., Lin, X., Starks, D. C., Dale, A., Gaster, K., De, P. K., & Dey, N. (2024) · American Journal of Cancer Research · doi:10.62347/htvu4235 · Cited by 2
Marion, S., Facchino, S., Cheng-Oviedo, S. G., & Collin, Y. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001113 · Cited by 2
Cancer therapy related cardiac dysfunction as a result of Panitumumab
Senechal, I., Vogiatzakis, N., Andrés, M. S., Tong, J., Ramalingam, S., Rosen, S. D., Lyon, A. R., & Nazir, M. S. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00223-3 · Cited by 2
In Silico Methods and Targeted Receptors Used in Cancer Studies
Bıçak, B., & Kecel‐Gunduz, S. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_421 · Cited by 1
Shi, Y., Wang, X., Xi, X., Wang, M., Guo, J. H., Zhang, X., Chen, D., & Yang, W. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261445706 · Cited by 1
Agy, F. E., Bahja, S., Abkari, M. E., Ibrahimi, S. A., Rhazi, K. E., Chbani, L., & Lahmidani, N. (2025) · Revista Española de Patología · doi:10.1016/j.patol.2025.100840 · Cited by 1
Pevzner, K., Simchi, N., Arad, G., & Seger, E. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4418-8_10 · Cited by 1
Lebedeva, A. A., Kavun, A., Belova, E. V., Antonova, T. G., & Semenova, A. B. (2025) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2025-11-1-0-1 · Cited by 1
Khan, F., Polydorides, A. D., Paulsen, J. D., Chen, W., Vazzano, J. L., Huber, A., Papke, D. J., Sharifai, N., Stashek, K. M., Ruz‐Caracuel, I., et al. (2026) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002555 · Cited by 1
Biomarkers as a Therapeutic Approach in Colorectal Carcinoma
Effendi-Ys, R., Rey, A., & Rey, I. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004189 · Cited by 1
Naseri, S., Shukla, S., & Vagha, S. J. (2024) · Pan African Medical Journal · doi:10.11604/pamj.2024.48.39.38445 · Cited by 1
Kahraman, S., ÇELEBİ, S. N. Ö., Kuratmer, A. D., Karahan, İ., Dede, D. S., ŞENDUR, M. A. N., Akıncı, M. B., Erol, C., Hızal, M., Bilgin, B., et al. (2025) · Journal of Oncological Sciences · doi:10.37047/jos.galenos.2025.2024.103340
Recent updates of clinical trials for colorectal cancer
Prajapati, V. D., Roy, S. D., Shinde, S., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00012-x
Current treatment options of HER2+ metastatic colorectal carcinoma
Liberko, M., & Soumarová, R. (2024) · Onkologie · doi:10.36290/xon.2024.039
Low frequency of HER2 expression in colorectal cancer: A Tunisian single-center study
Lazreg, K. B., Majdoub, W., Bdioui, A., Krifa, M., Lajmi, Z., Belkacem, O., Alaya, M., Mestiri, S., Hmissa, S., & Missaoui, N. (2025) · Cellular and Molecular Biology · doi:10.14715/cmb/2025.71.7.6
Itkin, B., & Burney, I. A. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_240_24
Ogurchyenok, N. E., Agapov, M. Y., & Раскин, Г. А. (2025) · Clinical Case in Oncology · doi:10.62546/3034-1477-2024-2-3-7-17
Metadata
- Authors
- Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S.
- Affiliations
- Medical Oncology Unit 3, Veneto Institute of Oncology IRCCS, Padua, Italy
- Istituto Oncologico Veneto (IT)
- University of Padua (IT)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 219-232
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280492853
- Cited by
- 95
- References
- 75
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 34 · 2023: 17 · 2022: 7
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2, metastatic colorectal cancer, HER2 mutation, HER2 amplification, predictive biomarkers, prognostic factors, anti-EGFR therapy resistance, targeted therapy, therapeutic target
- MeSH terms
- Humans, Prognosis, Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.